As the world’s leading minimally invasive glaucoma surgery (MIGS) platform,1 iStent technologies have been shown to reduce topical medication burden by 69%,2 with this reduction sustained for up to seven years.3 By reducing reliance on topical eye drops, iStent technologies have also been associated with a 72% reduction in the proportion of patients experiencing severe ocular surface disease symptoms.4
Treating a patient’s glaucoma with iStent infinite can have the added benefit of assisting the cornea. Whether implanted in conjunction with cataract surgery or as a standalone procedure, iStent technologies have demonstrated significant and durable improvements in quality of life.5
Visit: glaukos.net.au
References
- Based on units sold.
- Ahmed IIK, De Francesco T, Singh K, et al; HORIZON Investigators. Long-term outcomes from the HORIZON randomized trial for a Schlemm’s canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742-51. doi: 10.1016/j.ophtha.2022.02.021.
- Hengerer FH, Auffarth GU, Conrad-Hengerer I. 7-year efficacy and safety of iStent inject trabecular micro-bypass in combined and standalone usage. Adv Ther. 2024;41:1481-1495. doi: 10.1007/s12325-024-02788-y.
- Schweitzer JA, Hauser WH, Berdahl JP, et al. Prospective interventional cohort study of ocular surface disease changes in eyes after trabecular micro-bypass stent(s) implantation (iStent or iStent inject) with phacoemulsification. Ophthalmol Ther. 2020;9(4):941-953. doi: 10.1007/s40123-020-00290-6.
- Samuelson TW, Singh IP, Katz LJ, et al. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject pivotal trial. Am J Ophthalmol. 2021;229:220-229. doi: 10.1016/j.ajo.2021.03.007.
